Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma

References

• Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1964;283(7335):702–703.
   Google Scholar
• Siu LLP, Chan JKC, Kwong YL, et al. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol. 2002;17(2):539–554.
   PubMed Web of Science ®Google Scholar
• Pallesen G, Hamilton-Dutoit SJ, Rowe M, et al. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337(8737):320–322.
   PubMed Web of Science ®Google Scholar
• Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007;110(3):972–978.
   PubMed Web of Science ®Google Scholar
• Listed N. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89(11):3909–3918.
   PubMed Web of Science ®Google Scholar
• Lynch RC, Gratzinger D, Advani RH. Clinical impact of the 2016 update to the WHO Lymphoma Classification. Curr Treat Options Oncol. 2017;18(10):60.
   PubMed Web of Science ®Google Scholar
• Ito Y, Kimura H, Maeda Y, et al. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma. Clin Cancer Res. 2012;18(15):4183–4190.
   PubMed Web of Science ®Google Scholar
• Wang Z-Y, Liu Q-F, Wang H, et al. Clinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapy. Blood. 2012;120(10):2003–2010.
   PubMed Web of Science ®Google Scholar
• Hohaus S, Santangelo R, Giachelia M, et al. The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma. Clin Cancer Res. 2011;17(9):2885–2892.
   PubMed Web of Science ®Google Scholar
• Gandhi MK, Lambley E, Burrows J, et al. Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clin Cancer Res. 2006;12(2):460–464.
   PubMed Web of Science ®Google Scholar
• Westmoreland KD, Montgomery ND, Stanley CC, et al. Plasma Epstein‐Barr virus DNA for pediatric Burkitt lymphoma diagnosis, prognosis and response assessment in Malawi. Int J Cancer. 2017;140(11):2509–2516.
   PubMed Web of Science ®Google Scholar
• Okamoto A, Yanada M, Inaguma Y, et al. The prognostic significance of EBV DNA load and EBER status in diagnostic specimens from diffuse large B-cell lymphoma patients. Hematol Oncol. 2017;35(1):87–93.
   PubMed Web of Science ®Google Scholar
• Tisi MC, Cupelli E, Santangelo R, et al. Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma. Leuk Lymphoma. 2016;57(3):628–634.
   PubMed Web of Science ®Google Scholar
• Xu J, Li P, Chai J, et al. The clinicopathological and molecular features of sinusoidal large B-cell lymphoma. Mod Pathol. 2021;34(5):922–933.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282.
   PubMed Web of Science ®Google Scholar
• Yoon S, Jeon Y, Paik J, et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. Histopathology. 2008;53(2):205–217.
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830–837.
   PubMed Web of Science ®Google Scholar
• Robinson JT, Thorvaldsdóttir H, Wenger AM, et al. Variant review with the integrative genomics viewer. Cancer Res. 2017;77(21):e31–e34.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zheng X, Chen B, et al. The clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2017;58(10):2349–2355.
   PubMed Web of Science ®Google Scholar
• Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein‐Barr virus (EBV) genomes in the serum of patients with EBV‐associated Hodgkin's disease. Int J Cancer. 1999;84(4):442–448.
   PubMed Web of Science ®Google Scholar
• Morales D, Beltran B, De Mendoza FH, et al. Epstein-Barr virus as a prognostic factor in de novo nodal diffuse large B-cell lymphoma. Leuk Lymphoma. 2010;51(1):66–72.
   PubMed Web of Science ®Google Scholar
• Keane C, Tobin J, Gunawardana J, et al. The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. Eur J Haematol. 2019;103(3):200–207.
   PubMed Web of Science ®Google Scholar
• Chi YO, Li L, Xu-Monette ZY, et al. Prevalence and clinical implications of Epstein-Barr virus infection in de novo diffuse large B-Cell lymphoma in Western countries. Clin Cancer Res. 2014;20(9):2338–2349.
   PubMed Web of Science ®Google Scholar
• Nikolich-Žugich J. Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections. Nat Rev Immunol. 2008;8(7):512–522.
   PubMed Web of Science ®Google Scholar
• Berglund M, Thunberg U, Amini R-M, et al. Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Mod Pathol. 2005;18(8):1113–1120.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
   PubMed Web of Science ®Google Scholar
• Ziarkiewicz M, Wołosz D, Dzieciątkowski T, et al. Epstein-Barr virus-positive diffuse large B cell lymphoma in the experience of a tertiary medical center in Poland. Arch Immunol Ther Exp. 2016;64(2):159–169.
   PubMed Web of Science ®Google Scholar
• Sangam K, Kumar Y, Minz RW, et al. Patients with plasma cell disorders have high EBV DNA in peripheral blood than the general population. Pathol Oncol Res. 2020;26(4):2789–2794.
   PubMed Web of Science ®Google Scholar
• Kanakry JA, Hegde AM, Durand CM, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016;127(16):2007–2017.
   PubMed Web of Science ®Google Scholar
• Ok CY, Ye Q, Li L, et al. Age cutoff for Epstein-Barr virus-positive diffuse large B-cell lymphoma-is it necessary? Oncotarget. 2015;6(16):13933–13945.
   PubMedGoogle Scholar
• Montes-Moreno S, Odqvist L, Diaz-Perez JA, et al. EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol. 2012;25(7):968–982.
   PubMed Web of Science ®Google Scholar
• Ok CY, Papathomas TG, Medeiros LJ, et al. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013;122(3):328–340.
   PubMed Web of Science ®Google Scholar
• Grywalska E, Pasiarski M, Sosnowska-Pasiarska B, et al. Programmed cell death 1 expression and Epstein-Barr virus infection in chronic lymphocytic leukaemia: a prospective cohort study. Cancer Manag Res. 2019;11:7605–7618.
   PubMed Web of Science ®Google Scholar
• Ma S-D, Xu X, Jones R, et al. PD-1/CTLA-4 blockade inhibits Epstein-Barr virus-induced lymphoma growth in a cord blood humanized-mouse model. PLoS Pathog. 2016;12(5):e1005642.
   PubMed Web of Science ®Google Scholar
• Quan L, Chen X, Liu A, et al. PD-1 blockade can restore functions of T-cells in Epstein-Barr virus-positive diffuse large B-cell lymphoma in vitro. PLoS One. 2015;10(9):e0136476.
   PubMed Web of Science ®Google Scholar